ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1667150
This article is part of the Research TopicIntegrating Nutrition in Cancer Therapy: Approaches to Improve Patient Outcomes and SurvivalView all 11 articles
Long-term Nutrition Therapy leads to survival benefit in Head and Neck Cancer Patients Receiving Targeted or Immunotherapy. A retrospective Cohort study with Real-World Data
Provisionally accepted- 1Doctoral School of Health Sciences, Semmelweis University, Budapest, Hungary
- 2Department of Dietetics and Nutritional Sciences, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary
- 3Semmelweis Egyetem, Budapest, Hungary
- 4MedicalScan Ltd., Budapest, Hungary
- 5Department of Oncology, Radiumhospital, Oslo University Hospital Comprehensive Cancer Centre, Oslo, Norway
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Nutritional status is one of the most important prognostic factors of survival in patients with recurrent or metastatic head and neck cancer (R/M HNC), and it can be positively influenced by medical nutrition therapy (MNT). To evaluate the impact of MNT, we collected Real-World Data on its use in R/M HNC patients receiving molecular targeted therapy (TT) or immunotherapy (IT) and examined the correlation between survival and duration of MNT. Methods: This retrospective, analytical, cohort study utilized data extracted from the electronic health records of the Hungarian National Health Insurance Fund Management. In total, data from 1,660 HNC patients treated between 2018 and 2023 were used. Statistical analysis was conducted using the Kaplan-Meier method, log-rank test, and Cox regression analysis. Survival was assessed over a follow-up period of 730 days. Results: During the study period, 993 of 1,660 patients (55.9%) aged over 18 received molecular TT, and 667 (40.1%) patients received IT. Patients were categorized into three groups based on whether they received MNT during treatment and the duration of MNT. When comparing these groups, we found that patients who received MNT for more than 6 months had better survival in both the targeted therapy group (HR = 0.49, 95% CI = 0.36–0.69, p<0.001) and the immunotherapy group (HR = 0.4, 95% CI = 0.22–0.72, p=0.002). Conclusions: Our study demonstrates a positive correlation between long-term use of MNT — defined as treatment lasting more than six months — and overall survival (OS) in patients with R/M HNC This is a provisional file, not the final typeset article receiving TT or IT. These findings underscore the importance of early identification of inadequate nutritional status, as well as the timely initiation and sustained application of MNT. The main limitation of the research is that it is based on retrospective data and from only one country. Results may vary in other countries due to differences in treatment protocols and the composition of nutritional formulas.
Keywords: head and neck neoplasms1, nutritional support2, immunotherapy3, Molecular targeted therapy4, surviva5
Received: 16 Jul 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Belák, Pálfi, Molnár, Blasszauer, Reibl and Lövey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Erzsébet Pálfi, palfi.erzsebet@semmelweis.hu
Andrea Molnár, dr.molnarandrea.rd@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.